Latest topics page 44
Topics ordered by most recent activity across all 71 subcategories.
1,535 topics · page 44 of 52
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Open-label extensions: what survives and what does not
Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and…
|
+22 | 26 | 397 | 16mo |
|
A promotion I argued against, and why I lost
Posting this under the heading it deserves: A promotion I argued against, and why I lost Everything below is what sits behind that. Nominating something for promotion into the documentation commons. The topic…
|
+148 | 162 | 3.9k | 16mo |
|
Preservatives: function, testing, and limits
Preservatives: function, testing, and limits — setting out what I have, and where I think it stops being reliable. Working through the identity arithmetic and I would like it checked. tirzepatide has a…
|
+23 | 27 | 3.7k | 16mo |
|
Why cagrilintide alone is discussed so much less than in combination
Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
|
+93 | 108 | 35k | 16mo |
|
What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset
Asking directly, because I could not find a straight answer: What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Session topic: SURMOUNT-1 ( N Engl J Med ,…
|
+112 | 130 | 2.2k | 16mo |
|
Documenting a supplier's response to a discrepancy — does this still hold?
Documenting a supplier's response to a discrepancy — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…
|
+47 | 52 | 58k | 16mo |
|
Second pass at: A single out-of-range value on an otherwise normal panel
Second pass at: A single out-of-range value on an otherwise normal panel Writing it up because I had to work it out twice and would rather nobody else did. General question, not a request for advice about my…
|
+9 | 13 | 8.5k | 16mo |
|
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold?
The question in the title: Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen SURMOUNT-2 ( Lancet ,…
|
+60 | 66 | 12k | 16mo |
|
Second pass at: Cross-border purchase within the EU: the actual rules
Posting this under the heading it deserves: Second pass at: Cross-border purchase within the EU: the actual rules Everything below is what sits behind that. Documenting an access outcome, dated, because…
|
+135 | 139 | 8.7k | 16mo |
|
What happens after your first post: likes, trust levels, and why none of it matters much
Asking directly, because I could not find a straight answer: What happens after your first post: likes, trust levels, and why none of it matters much I want to check my reasoning rather than get a conclusion.…
|
+15 | 19 | 17k | 16mo |
|
Pancreatitis history and the risk calculus — a second dataset
Pancreatitis history and the risk calculus — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. General question, not a request for advice about my own care —…
|
+24 | 28 | 36k | 16mo |
|
Patterns that reliably precede a problem, documented
Patterns that reliably precede a problem, documented — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually better than anywhere else I…
|
+3 | 7 | 31k | 16mo |
|
Counter-ion form: the field almost nobody reports — one year on
On the subject in the title: Counter-ion form: the field almost nobody reports — one year on Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a…
|
+121 | 139 | 31k | 16mo |
|
Coverage for the indication versus for the drug — a second dataset
On the subject in the title: Coverage for the indication versus for the drug — a second dataset Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is…
|
+46 | 50 | 41k | 16mo |
|
Assessing a warm arrival: the decision process
Posting this under the heading it deserves: Assessing a warm arrival: the decision process Everything below is what sits behind that. A logistics question, since the answers here are usually better than…
|
+15 | 19 | 3.3k | 16mo |
|
Coming back to: Column chemistry choices for a 40-residue peptide
On the subject in the title: Column chemistry choices for a 40-residue peptide Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise be.…
|
2 | 43k | 16mo | |
|
Second pass at: Manufacturer assistance programmes and their eligibility rules
Second pass at: Manufacturer assistance programmes and their eligibility rules — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in…
|
+13 | 17 | 1.8k | 16mo |
|
Research-use-only status: what it means legally and practically — a second dataset
Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2 (…
|
+109 | 125 | 2k | 16mo |
|
How compounding permissions changed when supply normalised
Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised Structured report rather than an opinion, following the format the maintainers asked…
|
+30 | 34 | 51k | 16mo |
|
Second pass at: Domestic fridge temperature mapping: a cheap experiment
Posting this under the heading it deserves: Second pass at: Domestic fridge temperature mapping: a cheap experiment Everything below is what sits behind that. I have read the maintained page on this and I…
|
2 | 30k | 16mo | |
|
Oxidation and deamidation mass shifts, tabulated
Posting this under the heading it deserves: Oxidation and deamidation mass shifts, tabulated Everything below is what sits behind that. Working through the identity arithmetic and I would like it checked.…
|
+67 | 76 | 21k | 16mo |
|
Validating a method you did not develop — does this still hold?
Validating a method you did not develop — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to understand what this number means…
|
+128 | 148 | 47k | 16mo |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since
Posting this under the heading it deserves: Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…
|
+125 | 132 | 39k | 16mo |
|
Biased agonism: a real phenomenon, an over-used explanation
Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…
|
+130 | 135 | 23k | 16mo |
|
Introducing myself and asking whether my planned first topic belongs anywhere
Introducing myself and asking whether my planned first topic belongs anywhere Writing it up because I had to work it out twice and would rather nobody else did. I want to check my reasoning rather than get a…
|
+13 | 18 | 4.2k | 16mo |
|
Maintainer handover: how it works
On the subject in the title: Maintainer handover: how it works Working notes rather than a conclusion. Process question about how this site works. I have read the guidelines and the trust-level page and I…
|
+76 | 82 | 14k | 16mo |
|
One lot is one lot: when a report becomes a pattern — the long version
One lot is one lot: when a report becomes a pattern — the long version — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
|
+137 | 152 | 46k | 16mo |
|
Journal club: SURMOUNT-OSA and a hard endpoint in a soft field
Posting this under the heading it deserves: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with SCALE ( N Engl J…
|
+47 | 51 | 617 | 16mo |
|
Charge states for a 4 kDa peptide, worked through
On the subject in the title: Charge states for a 4 kDa peptide, worked through Working notes rather than a conclusion. Working through the identity arithmetic and I would like it checked. retatrutide has a…
|
+124 | 146 | 15k | 16mo |
|
SNAC and the mechanism of oral peptide absorption — the long version
SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
|
+32 | 36 | 6.8k | 16mo |